147 Ruxolitinib reverses accelerated tumor growth of RDEB-cSCCs in a xenograft mouse model

The most lethal complication of recessive dystrophic epidermolysis bullosa (RDEB) is the development of aggressive cSCCs, which lead the high mortality rates in RDEB patients. RDEB results from mutations in COL7A1 which impair the function of type VII collagen (C7), resulting in blister formation. C7 deficiency directly interferes with the healing process by altering the wound microenvironment. These abnormalities increase TGF- ß1 signaling and lead to a constitutively active JAK-STAT pathway. Currently, the available treatments for locally advanced or metastatic cSCC are very limited.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research